Diplomat Pharmacy Inc (DPLO) is Initiated by Avondale to Mkt Outperform, Price Target at $38

Diplomat Pharmacy Inc (DPLO) was Initiated by Avondale to “Mkt Outperform” and the brokerage firm has set the Price Target at $38. Avondale advised their investors in a research report released on Apr 19, 2016.

Many Wall Street Analysts have commented on Diplomat Pharmacy Inc. Diplomat Pharmacy Inc was Initiated by Credit Suisse to “Neutral” on Mar 16, 2016. Diplomat Pharmacy Inc was Downgraded by JP Morgan to ” Neutral” on Mar 1, 2016. Mizuho Downgraded Diplomat Pharmacy Inc on Mar 1, 2016 to ” Neutral”, Price Target of the shares are set at $30.

On the company’s financial health, Diplomat Pharmacy Inc reported $0.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Feb 29, 2016. Analyst had a consensus of $0.20. The company had revenue of $987.00 million for the quarter, compared to analysts expectations of $969.69 million. The company’s revenue was up 61.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.08 EPS.

Diplomat Pharmacy Inc opened for trading at $30.06 and hit $31.03 on the upside on Monday, eventually ending the session at $30.62, with a gain of 1.66% or 0.5 points. The heightened volatility saw the trading volume jump to 3,41,551 shares. Company has a market cap of $1,976 M.

In a different news, on Apr 18, 2016, Atheer A Kaddis (EVP of Sales & Strategic Align) sold 24,650 shares at $30.00 per share price. According to the SEC, on Dec 8, 2015, Philip R Hagerman (Chairman and CEO) sold 2,300,000 shares at $33.60 per share price. On Dec 2, 2015, Gary W Kadlec (President) sold 30,000 shares at $35.08 per share price, according to the Form-4 filing with the securities and exchange commission.

Diplomat Pharmacy Inc. (Diplomat) is an independent specialty pharmacy in the United States. The Company provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups hospitals and health systems. The Company offers services in Specialty Drug Dispensing which includes its specialty infusion pharmacy services. The specialty drug dispensing services include Patient Care Coordination Clinical Services Compliance and Persistency Programs Patient Financial Assistance Specialty Pharmacy Training/Consulting (Diplomat University) Benefits Investigation Prior Authorization Risk Evaluation and Medication Strategy (REMS) Retail Specialty Services Hospital and Health System Services and Hub Services. The Company help patients adhere to complicated medication therapies process refills and manage any side effects and insurance concerns to ensure they get the standard of care.

Diplomat Pharmacy Inc

Leave a Reply

Diplomat Pharmacy Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Diplomat Pharmacy Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.